08:17 AM EDT, 10/07/2025 (MT Newswires) -- Telomir Pharmaceuticals ( TELO ) said Tuesday that preclinical results show that its investigational therapy Telomir-1 reactivated two tumor suppressor genes, potentially preventing the spread of cancer and improving responses to chemotherapy.

The results showed that the experimental therapy reactivated the MASPIN and RASSF1A genes through DNA methylation reset in prostate cancer models, the company said.

Tumors often silence the genes, disabling the body's natural defenses, the company said.

Telomir said it is advancing Telomir-1 through preclinical development and studies that could allow for an investigational new drug application with the US Food and Drug Administration.

Shares of the company were up nearly 20% in recent premarket activity Tuesday.